Fig. 3 | npj Parkinson's Disease

Fig. 3

From: Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model

Fig. 3

VH14*PEST treatment counteracts insults in nigrostriatal dopaminergic tone induced by synucleinopathy. a Assessment of TH+ immunoreactivity in the substantia nigra and striatum. VH14*PEST reveals preservation of striatal innervation in comparison to saline-treated and NbSyn87*PEST-treated animals. Evidence of protection is strongest in the dorsolateral striatum (scale bars: 100 and 25 μm). b Immunostaining of dopamine transporter (DAT) expression in the striatum shows modest improvement in VH14*PEST treatment animals compared to saline-treated animals (scale bar: 25 μm). c Quantification of striatal TH optical density (saline—n = 7, VH14*PEST—n = 7, NbSyn87*PEST—n = 8), stereological cell counts of TH-labeled cells in the substantia nigra (saline—n = 7, VH14*PEST—n = 8, NbSyn87*PEST—n = 7), striatal DAT optical density (saline—n = 7, VH14*PEST—n = 8, NbSyn87*PEST—n = 7), and the concentration of striatal dopamine (saline—n = 4, VH14*PEST—n = 7, NbSyn87*PEST—n = 6). All data were analyzed via one-way ANOVA with Tukey's post hoc comparisons (all *p < 0.05, **p < 0.01, or as indicated on figure)

Back to article page